CN104039789B - 四氮杂-环戊二烯并[a]茚基及其作为正向变构调节剂的用途 - Google Patents
四氮杂-环戊二烯并[a]茚基及其作为正向变构调节剂的用途 Download PDFInfo
- Publication number
- CN104039789B CN104039789B CN201280062522.3A CN201280062522A CN104039789B CN 104039789 B CN104039789 B CN 104039789B CN 201280062522 A CN201280062522 A CN 201280062522A CN 104039789 B CN104039789 B CN 104039789B
- Authority
- CN
- China
- Prior art keywords
- mmol
- title compound
- equiv
- tetraaza
- hplc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 C*c1ccccc1OCCc1ncccc1 Chemical compound C*c1ccccc1OCCc1ncccc1 0.000 description 17
- HBDLOZGENWWDQG-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1Oc1ccccc1C(O)=O)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1Oc1ccccc1C(O)=O)=O HBDLOZGENWWDQG-UHFFFAOYSA-N 0.000 description 1
- FZQLPFUATCGVEL-UHFFFAOYSA-N CC(C)(C)OC(N1Cc2n[n](cc(C)c(C)n3)c3c2C1)=O Chemical compound CC(C)(C)OC(N1Cc2n[n](cc(C)c(C)n3)c3c2C1)=O FZQLPFUATCGVEL-UHFFFAOYSA-N 0.000 description 1
- XRWBFVHNFKEYFX-UHFFFAOYSA-N CC(C)(C)OC(N1Cc2n[n]3c(C)c(C)cnc3c2C1)=O Chemical compound CC(C)(C)OC(N1Cc2n[n]3c(C)c(C)cnc3c2C1)=O XRWBFVHNFKEYFX-UHFFFAOYSA-N 0.000 description 1
- MDZUKLDGEBSXDU-UHFFFAOYSA-N CC(C)N(CC1)CCC1Oc1c(C)ccc(F)c1 Chemical compound CC(C)N(CC1)CCC1Oc1c(C)ccc(F)c1 MDZUKLDGEBSXDU-UHFFFAOYSA-N 0.000 description 1
- LEBZENRHVPZLGO-ZDUSSCGKSA-N CC(C)N(CC1)C[C@H]1Oc1c(C)ccc(F)c1 Chemical compound CC(C)N(CC1)C[C@H]1Oc1c(C)ccc(F)c1 LEBZENRHVPZLGO-ZDUSSCGKSA-N 0.000 description 1
- RRVIHWSQIZWXIJ-UHFFFAOYSA-N CC(C)c(ccc(F)c1)c1OC1CCN(C)CC1 Chemical compound CC(C)c(ccc(F)c1)c1OC1CCN(C)CC1 RRVIHWSQIZWXIJ-UHFFFAOYSA-N 0.000 description 1
- JDGYUBGXUUYRIE-UHFFFAOYSA-N CC(C)c(ccc(F)c1)c1OCCc1cccnc1 Chemical compound CC(C)c(ccc(F)c1)c1OCCc1cccnc1 JDGYUBGXUUYRIE-UHFFFAOYSA-N 0.000 description 1
- YCPVHLGWCWAIJE-GJAAFAAWSA-N CC(C)c(ccc([F]C(C1)NC[C@H]1Oc1c(C)ccc(F)c1)c1)c1O[C@H]1CN(CC(F)(F)F)CC1 Chemical compound CC(C)c(ccc([F]C(C1)NC[C@H]1Oc1c(C)ccc(F)c1)c1)c1O[C@H]1CN(CC(F)(F)F)CC1 YCPVHLGWCWAIJE-GJAAFAAWSA-N 0.000 description 1
- SUGFJDXELZYCSP-UHFFFAOYSA-N CC(COc1cc(F)ccc1C(N(Cc1c2nc3C)Cc1n[n]2c(C)c3Cl)=O)N(C)C Chemical compound CC(COc1cc(F)ccc1C(N(Cc1c2nc3C)Cc1n[n]2c(C)c3Cl)=O)N(C)C SUGFJDXELZYCSP-UHFFFAOYSA-N 0.000 description 1
- RUUYOBUPHNZLCY-UHFFFAOYSA-N CC(N(CC1)CC1/C=[O]/c(cc(cc1)F)c1[IH]C)=C Chemical compound CC(N(CC1)CC1/C=[O]/c(cc(cc1)F)c1[IH]C)=C RUUYOBUPHNZLCY-UHFFFAOYSA-N 0.000 description 1
- QRAJOFBJXIJHGG-UHFFFAOYSA-N CC1[n]2nc(CN(C3)C(c4c(CN5CCNCC5)cccc4)=O)c3c2N=C(C)C1Cl Chemical compound CC1[n]2nc(CN(C3)C(c4c(CN5CCNCC5)cccc4)=O)c3c2N=C(C)C1Cl QRAJOFBJXIJHGG-UHFFFAOYSA-N 0.000 description 1
- WHVUGPXBYGXZCU-UHFFFAOYSA-N CCOc(cc(cc1)F)c1C(O)=O Chemical compound CCOc(cc(cc1)F)c1C(O)=O WHVUGPXBYGXZCU-UHFFFAOYSA-N 0.000 description 1
- LEMWSBVOCYNPDF-HNNXBMFYSA-N Cc([n]1nc(CN(C2)C(c(c(O[C@@H]3CNCCC3)c3)ccc3F)=O)c2c1nc1C)c1Cl Chemical compound Cc([n]1nc(CN(C2)C(c(c(O[C@@H]3CNCCC3)c3)ccc3F)=O)c2c1nc1C)c1Cl LEMWSBVOCYNPDF-HNNXBMFYSA-N 0.000 description 1
- WWKJBEFNAZFJRL-UHFFFAOYSA-N Cc([n]1nc(CN(C2)C(c(ccc(F)c3)c3OCCc3c[n](C)nc3)=O)c2c1nc1C)c1Cl Chemical compound Cc([n]1nc(CN(C2)C(c(ccc(F)c3)c3OCCc3c[n](C)nc3)=O)c2c1nc1C)c1Cl WWKJBEFNAZFJRL-UHFFFAOYSA-N 0.000 description 1
- IORPIVPBCHIHMJ-BCDXTJNWSA-N Cc([n]1nc(CN(C2)C(c(ccc(F)c3)c3O[C@H](C3)C[C@@H]4N(C)[C@H]3COC4)=O)c2c1nc1C)c1Cl Chemical compound Cc([n]1nc(CN(C2)C(c(ccc(F)c3)c3O[C@H](C3)C[C@@H]4N(C)[C@H]3COC4)=O)c2c1nc1C)c1Cl IORPIVPBCHIHMJ-BCDXTJNWSA-N 0.000 description 1
- VVBGDZCCVYEUNW-INIZCTEOSA-N Cc([n]1nc(CN(C2)C(c(cccc3)c3O[C@@H]3CN(C)CCC3)=O)c2c1nc1C)c1Cl Chemical compound Cc([n]1nc(CN(C2)C(c(cccc3)c3O[C@@H]3CN(C)CCC3)=O)c2c1nc1C)c1Cl VVBGDZCCVYEUNW-INIZCTEOSA-N 0.000 description 1
- UJRNLVCRNPFYTL-UHFFFAOYSA-N Cc([n]1nc(CN(C2)C(c3c(CN4CCN(C)CCC4)cccc3)=O)c2c1nc1C)c1Cl Chemical compound Cc([n]1nc(CN(C2)C(c3c(CN4CCN(C)CCC4)cccc3)=O)c2c1nc1C)c1Cl UJRNLVCRNPFYTL-UHFFFAOYSA-N 0.000 description 1
- IKPVCIISXVKZJG-UHFFFAOYSA-N Cc([n]1nc(CN(C2)C(c3ccccc3C=C3CCN(C)CC3)=O)c2c1nc1C)c1Cl Chemical compound Cc([n]1nc(CN(C2)C(c3ccccc3C=C3CCN(C)CC3)=O)c2c1nc1C)c1Cl IKPVCIISXVKZJG-UHFFFAOYSA-N 0.000 description 1
- PSWVUNZJMXNJJG-KRWDZBQOSA-N Cc([n]1nc(CN(C2)C(c3ccccc3CO[C@@H]3CNCCC3)=O)c2c1nc1C)c1Cl Chemical compound Cc([n]1nc(CN(C2)C(c3ccccc3CO[C@@H]3CNCCC3)=O)c2c1nc1C)c1Cl PSWVUNZJMXNJJG-KRWDZBQOSA-N 0.000 description 1
- ZWOMGIIQCKFLST-UHFFFAOYSA-N Cc([n]1nc(CN(C2)C(c3ccccc3OC3CCN(C)CC3)=O)c2c1nc1C)c1F Chemical compound Cc([n]1nc(CN(C2)C(c3ccccc3OC3CCN(C)CC3)=O)c2c1nc1C)c1F ZWOMGIIQCKFLST-UHFFFAOYSA-N 0.000 description 1
- YKJJHFZHGFDPLZ-UHFFFAOYSA-N Cc([n]1nc(CN(C2)C(c3ccccc3OCCNC)=O)c2c1nc1C)c1Cl Chemical compound Cc([n]1nc(CN(C2)C(c3ccccc3OCCNC)=O)c2c1nc1C)c1Cl YKJJHFZHGFDPLZ-UHFFFAOYSA-N 0.000 description 1
- GOJRPQAKRPFUHO-UHFFFAOYSA-N Cc([n]1nc(CNC2)c2c1nc1C)c1F Chemical compound Cc([n]1nc(CNC2)c2c1nc1C)c1F GOJRPQAKRPFUHO-UHFFFAOYSA-N 0.000 description 1
- KYVNWLCABWSMRG-UHFFFAOYSA-N Cc(c(OC1CCN(CCF)CCC1)c1)ccc1F Chemical compound Cc(c(OC1CCN(CCF)CCC1)c1)ccc1F KYVNWLCABWSMRG-UHFFFAOYSA-N 0.000 description 1
- IZKOLIWIOYJKLW-OAHLLOKOSA-N Cc(c(O[C@H](CC1)CN1C1CCOCC1)c1)ccc1F Chemical compound Cc(c(O[C@H](CC1)CN1C1CCOCC1)c1)ccc1F IZKOLIWIOYJKLW-OAHLLOKOSA-N 0.000 description 1
- YGJJJHPTNRKZFU-SNVBAGLBSA-N Cc(c(O[C@H]1CNCC1)c1)ccc1F Chemical compound Cc(c(O[C@H]1CNCC1)c1)ccc1F YGJJJHPTNRKZFU-SNVBAGLBSA-N 0.000 description 1
- YRYRIWCEJWXMDR-SNAWJCMRSA-N Cc1c(C)c(O/C=C/c2c[n](C)[n]c2)cc(F)c1 Chemical compound Cc1c(C)c(O/C=C/c2c[n](C)[n]c2)cc(F)c1 YRYRIWCEJWXMDR-SNAWJCMRSA-N 0.000 description 1
- XCHKKIMRHNCWOK-UHFFFAOYSA-N Cc1c(CN(CC2)CC2O)cccc1 Chemical compound Cc1c(CN(CC2)CC2O)cccc1 XCHKKIMRHNCWOK-UHFFFAOYSA-N 0.000 description 1
- LLQOZJLMBHICAY-UHFFFAOYSA-N Cc1c(CN(CC2)CCC2(C(F)(F)F)O)cccc1 Chemical compound Cc1c(CN(CC2)CCC2(C(F)(F)F)O)cccc1 LLQOZJLMBHICAY-UHFFFAOYSA-N 0.000 description 1
- AKJBRXBZNWFNRT-UHFFFAOYSA-N Cc1c[n]2nc(CN(C3)C(c(cccc4)c4N4CCN(C)CCC4)=O)c3c2nc1C Chemical compound Cc1c[n]2nc(CN(C3)C(c(cccc4)c4N4CCN(C)CCC4)=O)c3c2nc1C AKJBRXBZNWFNRT-UHFFFAOYSA-N 0.000 description 1
- IMMFFKGTZYMABG-UHFFFAOYSA-N Cc1c[n]2nc(CN(C3)C(c(cccc4)c4OCCN(C)C)=O)c3c2nc1 Chemical compound Cc1c[n]2nc(CN(C3)C(c(cccc4)c4OCCN(C)C)=O)c3c2nc1 IMMFFKGTZYMABG-UHFFFAOYSA-N 0.000 description 1
- GRVNOUKHAZXMJK-UHFFFAOYSA-N Cc1ccccc1CN1CCNCC1 Chemical compound Cc1ccccc1CN1CCNCC1 GRVNOUKHAZXMJK-UHFFFAOYSA-N 0.000 description 1
- MJRNRVDKDXBDNT-UHFFFAOYSA-N O=C(c(cccc1)c1OC(C(F)F)(F)F)N1Cc2n[n](cc(cn3)Cl)c3c2C1 Chemical compound O=C(c(cccc1)c1OC(C(F)F)(F)F)N1Cc2n[n](cc(cn3)Cl)c3c2C1 MJRNRVDKDXBDNT-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161578931P | 2011-12-22 | 2011-12-22 | |
| EP11195214.9 | 2011-12-22 | ||
| EP11195214.9A EP2607364A1 (en) | 2011-12-22 | 2011-12-22 | Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators |
| US61/578,931 | 2011-12-22 | ||
| US201261657978P | 2012-06-11 | 2012-06-11 | |
| EP12171415.8 | 2012-06-11 | ||
| US61/657,978 | 2012-06-11 | ||
| EP12171415.8A EP2674434A1 (en) | 2012-06-11 | 2012-06-11 | Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators |
| PCT/EP2012/004968 WO2013091773A1 (en) | 2011-12-22 | 2012-11-30 | Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104039789A CN104039789A (zh) | 2014-09-10 |
| CN104039789B true CN104039789B (zh) | 2016-09-07 |
Family
ID=48667735
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201280062522.3A Active CN104039789B (zh) | 2011-12-22 | 2012-11-30 | 四氮杂-环戊二烯并[a]茚基及其作为正向变构调节剂的用途 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9403835B2 (enExample) |
| EP (1) | EP2794608B1 (enExample) |
| JP (1) | JP6112316B2 (enExample) |
| CN (1) | CN104039789B (enExample) |
| AU (1) | AU2012357169B2 (enExample) |
| CA (1) | CA2860008C (enExample) |
| ES (1) | ES2606839T3 (enExample) |
| WO (1) | WO2013091773A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2813505A1 (en) * | 2013-06-14 | 2014-12-17 | Asceneuron SA | Tetraaza-cyclopenta[a]indenyl derivatives |
| GB201317363D0 (en) | 2013-10-01 | 2013-11-13 | Eisai Ltd | Novel compounds |
| CN106573928B (zh) * | 2014-08-26 | 2020-04-14 | 安斯泰来制药株式会社 | 2-氨基噻唑衍生物或其盐 |
| CA2976092A1 (en) * | 2015-02-11 | 2016-08-18 | Sunovion Pharmaceuticals Inc. | Fused dihydro-4h-pyrazolo[5,1-c][1,4]oxazinyl compounds and analogs for treating cns disorders |
| JP6116782B1 (ja) * | 2015-08-28 | 2017-04-19 | 積水メディカル株式会社 | ベンジル化合物 |
| SG10202100751YA (en) | 2016-07-29 | 2021-03-30 | Sunovion Pharmaceuticals Inc | Compounds and compositions and uses thereof |
| SG11202000669VA (en) | 2017-08-02 | 2020-02-27 | Sunovion Pharmaceuticals Inc | Isochroman compounds and uses thereof |
| KR102835667B1 (ko) | 2017-12-21 | 2025-07-21 | 애브비 바이오테크놀로지 리미티드 | Parp14 억제제로서의 퀴나졸리논 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002076987A1 (en) * | 2001-03-27 | 2002-10-03 | Neurogen Corporation | (oxo-pyrazolo[1,5a]pyrimidin-2-yl)alkyl-carboxamides |
| WO2008060488A1 (en) * | 2006-11-14 | 2008-05-22 | Merck & Co., Inc. | Tricyclic heteroaromatic compounds as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| WO2011137049A1 (en) * | 2010-04-30 | 2011-11-03 | Merck Sharp & Dohme Corp. | Heterocyclic quinolizine derived m1 receptor positive allosteric modulators |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2590316A1 (en) * | 2004-12-15 | 2006-06-22 | F. Hoffmann-La Roche Ag | Bi- and tricyclic substituted phenyl methanones as glycine transporter i (glyt-1) inhibitors for the treatment of alzheimer's disease |
| EP2813505A1 (en) * | 2013-06-14 | 2014-12-17 | Asceneuron SA | Tetraaza-cyclopenta[a]indenyl derivatives |
-
2012
- 2012-11-30 AU AU2012357169A patent/AU2012357169B2/en active Active
- 2012-11-30 WO PCT/EP2012/004968 patent/WO2013091773A1/en not_active Ceased
- 2012-11-30 CA CA2860008A patent/CA2860008C/en active Active
- 2012-11-30 JP JP2014547736A patent/JP6112316B2/ja active Active
- 2012-11-30 ES ES12798612.3T patent/ES2606839T3/es active Active
- 2012-11-30 CN CN201280062522.3A patent/CN104039789B/zh active Active
- 2012-11-30 US US14/366,901 patent/US9403835B2/en active Active
- 2012-11-30 EP EP12798612.3A patent/EP2794608B1/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002076987A1 (en) * | 2001-03-27 | 2002-10-03 | Neurogen Corporation | (oxo-pyrazolo[1,5a]pyrimidin-2-yl)alkyl-carboxamides |
| WO2008060488A1 (en) * | 2006-11-14 | 2008-05-22 | Merck & Co., Inc. | Tricyclic heteroaromatic compounds as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| WO2011137049A1 (en) * | 2010-04-30 | 2011-11-03 | Merck Sharp & Dohme Corp. | Heterocyclic quinolizine derived m1 receptor positive allosteric modulators |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2794608A1 (en) | 2014-10-29 |
| ES2606839T3 (es) | 2017-03-28 |
| US9403835B2 (en) | 2016-08-02 |
| WO2013091773A1 (en) | 2013-06-27 |
| CA2860008A1 (en) | 2013-06-27 |
| CA2860008C (en) | 2020-11-10 |
| AU2012357169A1 (en) | 2014-08-07 |
| JP2015502371A (ja) | 2015-01-22 |
| AU2012357169B2 (en) | 2017-03-30 |
| EP2794608B1 (en) | 2016-09-14 |
| US20150018343A1 (en) | 2015-01-15 |
| JP6112316B2 (ja) | 2017-04-12 |
| CN104039789A (zh) | 2014-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104039789B (zh) | 四氮杂-环戊二烯并[a]茚基及其作为正向变构调节剂的用途 | |
| CN103402996B (zh) | 可用于治疗年龄相关性黄斑变性(amd)的吲哚化合物或其类似物 | |
| TWI468402B (zh) | 降低β－類澱粉生成之化合物 | |
| CN104039787B (zh) | 激酶抑制剂 | |
| CN112424188A (zh) | 作为parp7抑制剂的哒嗪酮 | |
| CN110088096A (zh) | 作为泛素特异性蛋白酶7的抑制剂的哌啶衍生物 | |
| JP2025186255A (ja) | Ｋｖ１．３カリウムシェーカーチャネル遮断薬としてのアリール複素環式化合物 | |
| WO2025040170A1 (zh) | 作为CDKs抑制剂的新型并杂环类新化合物及其应用 | |
| JP2023532623A (ja) | ハンチントン病を処置するためのｈｔｔモジュレータ | |
| CN112996785A (zh) | 治疗性化合物 | |
| CN116075510A (zh) | 1H-苯并[d]咪唑衍生物作为TLR9抑制剂用于治疗纤维化 | |
| WO2024125532A1 (zh) | 作为CDKs抑制剂的新型并杂环类新化合物及其应用 | |
| CN113950477B (zh) | 颗粒体蛋白前体调节剂和其使用方法 | |
| CN105399698B (zh) | 芳杂环类衍生物及其在药物中的应用 | |
| CN113365696A (zh) | 药物化合物和其作为泛素特异性蛋白酶19(usp19)抑制剂的用途 | |
| CN114555592A (zh) | 作为m4激动剂的2-氮杂螺[3.4]辛烷衍生物 | |
| WO2024175024A1 (zh) | 作为CDKs抑制剂的新型并杂环类新化合物及其应用 | |
| TW202035419A (zh) | Ｕｄｐ糖基轉移酶抑制劑及其使用方法 | |
| EP3008068B1 (en) | Tetraaza-cyclopenta[a]indenyl derivatives | |
| EP2674434A1 (en) | Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators | |
| HK40056262B (zh) | 治疗性化合物 | |
| CN117203202A (zh) | 喹喔啉衍生物及其用途 | |
| HK40056262A (en) | Therapeutic compounds | |
| HK1228892B (en) | Kinase inhibitors | |
| HK1228892A1 (en) | Kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |